CA2256015A1 - Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic - Google Patents

Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic

Info

Publication number
CA2256015A1
CA2256015A1 CA002256015A CA2256015A CA2256015A1 CA 2256015 A1 CA2256015 A1 CA 2256015A1 CA 002256015 A CA002256015 A CA 002256015A CA 2256015 A CA2256015 A CA 2256015A CA 2256015 A1 CA2256015 A1 CA 2256015A1
Authority
CA
Canada
Prior art keywords
difluorobenzyl
carboxamide
triazole
antiepileptic
crystal modification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002256015A
Other languages
French (fr)
Other versions
CA2256015C (en
Inventor
Robert Portmann
Urs Christoph Hofmeier
Andreas Burkhard
Walter Scherrer
Martin Szelagiewicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4209650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2256015(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to CA2614926A priority Critical patent/CA2614926C/en
Publication of CA2256015A1 publication Critical patent/CA2256015A1/en
Application granted granted Critical
Publication of CA2256015C publication Critical patent/CA2256015C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Abstract

The invention relates to the novel modifications B and C of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of formula (I), its use for the treatment of epilepsy and pharmaceutical preparations comprising these crystal modifications.
CA002256015A 1997-06-10 1998-06-08 Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic Expired - Lifetime CA2256015C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2614926A CA2614926C (en) 1997-06-10 1998-06-08 Crystal modification c of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH1404/97 1997-06-10
CH140497 1997-06-10
PCT/EP1998/003428 WO1998056773A1 (en) 1997-06-10 1998-06-08 Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2614926A Division CA2614926C (en) 1997-06-10 1998-06-08 Crystal modification c of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic

Publications (2)

Publication Number Publication Date
CA2256015A1 true CA2256015A1 (en) 1998-12-17
CA2256015C CA2256015C (en) 2008-06-03

Family

ID=4209650

Family Applications (3)

Application Number Title Priority Date Filing Date
CA002256015A Expired - Lifetime CA2256015C (en) 1997-06-10 1998-06-08 Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic
CA002256013A Expired - Lifetime CA2256013C (en) 1997-06-10 1998-06-08 Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic
CA2614926A Expired - Lifetime CA2614926C (en) 1997-06-10 1998-06-08 Crystal modification c of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA002256013A Expired - Lifetime CA2256013C (en) 1997-06-10 1998-06-08 Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic
CA2614926A Expired - Lifetime CA2614926C (en) 1997-06-10 1998-06-08 Crystal modification c of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic

Country Status (37)

Country Link
US (6) US6740669B1 (en)
EP (2) EP0994863B1 (en)
JP (2) JP3672575B2 (en)
KR (2) KR100409168B1 (en)
CN (3) CN1298708C (en)
AR (4) AR012946A1 (en)
AT (2) ATE237599T1 (en)
AU (2) AU725517B2 (en)
BR (2) BR9804946A (en)
CA (3) CA2256015C (en)
CO (2) CO4940452A1 (en)
CY (1) CY2007014I1 (en)
CZ (2) CZ292481B6 (en)
DE (3) DE69813560T2 (en)
DK (2) DK0994863T3 (en)
ES (2) ES2192779T3 (en)
FR (1) FR07C0037I2 (en)
HK (3) HK1028241A1 (en)
HU (2) HU225153B1 (en)
ID (2) ID27660A (en)
IL (2) IL125733A (en)
LU (1) LU91345I2 (en)
MY (2) MY120156A (en)
NL (1) NL300284I2 (en)
NO (2) NO329315B1 (en)
NZ (2) NZ331370A (en)
PE (2) PE79799A1 (en)
PL (2) PL192114B1 (en)
PT (1) PT994864E (en)
RU (2) RU2198167C2 (en)
SI (2) SI0994863T1 (en)
SK (2) SK283734B6 (en)
TR (2) TR199801631T1 (en)
TW (2) TW403740B (en)
UY (1) UY25844A1 (en)
WO (2) WO1998056773A1 (en)
ZA (2) ZA984966B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW403740B (en) * 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
ES2299720T3 (en) * 2002-05-31 2008-06-01 Schering Corporation Polymorphic forms of an XANTINA-FOSFODIESTERASA V INHIBITOR.
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US7875284B2 (en) * 2006-03-10 2011-01-25 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US20090069390A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched rufinamide
CA2736703A1 (en) 2008-10-13 2010-04-22 Cipla Limited Process for the preparation of rufinamide
CN101768124B (en) * 2008-12-30 2012-01-04 北京本草天源药物研究院 Medicine crystal, preparation method and purpose thereof
IT1395736B1 (en) * 2009-08-04 2012-10-19 Dipharma Francis Srl CRYSTALLINE FORMS OF RUFINAMIDE
US8377973B2 (en) * 2009-09-04 2013-02-19 Tactical Therapeutics Inc Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
ES2498267T3 (en) 2010-04-30 2014-09-24 Laboratorios Lesvi, S.L. Improved procedure for the preparation of a rufinamide intermediate
EP2465853A1 (en) * 2010-12-14 2012-06-20 Laboratorios Lesvi, S.L. Polymorph of rufinamide and process for obtaining it
ITMI20110718A1 (en) * 2011-04-29 2012-10-30 Dipharma Francis Srl PROCEDURE FOR PURIFICATION OF RUFINAMIDE
WO2014013511A2 (en) * 2012-07-20 2014-01-23 Hetero Research Foundation Rufinamide solid dispersion
WO2021099481A1 (en) 2019-11-20 2021-05-27 Medichem, S.A. Solid composition containing rufinamide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992378A (en) 1973-12-26 1976-11-16 Eli Lilly And Company Fluoralkyl quinoxadinediones
US4156734A (en) * 1976-02-13 1979-05-29 Merck & Co., Inc. Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid
GB1511195A (en) 1976-10-18 1978-05-17 Ici America Inc Triazole derivatives
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4346097A (en) * 1980-09-30 1982-08-24 Warner-Lambert Company Method for treating convulsions with pyrazole-4-carboxamide derivatives
FI834666A (en) 1982-12-23 1984-06-24 Ciba Geigy Ag FOERFARANDE FOER FRAMSTAELLNING AV NYA ARALKYLTRIAZOLFOERENINGAR.
US4789680A (en) * 1982-12-23 1988-12-06 Ciba-Geigy Corporation Aralkyltriazole compounds
US4511572A (en) * 1983-03-18 1985-04-16 The University Of Kentucky Research Foundation Triazoline anticonvulsant drugs
PH22568A (en) * 1985-04-18 1988-10-17 Ciba Geigy Ag Fluorinated benzyl triazoles and pharmaceutical compositions containing the same
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
JPH02214504A (en) 1989-02-15 1990-08-27 Nissan Chem Ind Ltd Method for depositing crystal of compound having plural crystal forms
WO1991001724A1 (en) 1989-07-27 1991-02-21 G.D. Searle & Co. Renal-selective prodrugs for the treatment of hypertension
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
EP0556393B1 (en) 1990-11-06 2000-07-26 Yamanouchi Pharmaceutical Co. Ltd. Fused pyrazine derivative
JP2753911B2 (en) 1991-12-06 1998-05-20 キッセイ薬品工業株式会社 Crystal polymorph of N-tert-butyl-1-methyl-3,3-diphenylpropylamine hydrochloride and method for producing the same
DE4217952A1 (en) 1992-05-30 1993-12-02 Basf Ag Quinoxaline-2,3 (1H, 4H) diones
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5631373A (en) 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
GB9418443D0 (en) 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents
GB9419318D0 (en) 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents
ES2150105T3 (en) 1995-02-22 2000-11-16 Aventis Pharma Ltd PIRETANIDA AMORFA, POLYMORPHOS OF PIRETANIDA, PROCESS FOR ITS PREPARATION AND USE.
EP0918758B1 (en) * 1996-07-11 2002-05-02 Novartis AG Process for preparing 1-substituted 4-cyano-1,2,3-triazoles
TW403740B (en) 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide

Also Published As

Publication number Publication date
DE69811500D1 (en) 2003-03-27
CA2614926C (en) 2010-02-09
TR199801631T1 (en) 1999-06-21
NO983667L (en) 1998-12-17
NZ331370A (en) 2000-08-25
BR9804946A (en) 1999-08-24
NO983666D0 (en) 1998-08-11
ES2192779T3 (en) 2003-10-16
DE122007000051I2 (en) 2009-02-19
JP3672574B2 (en) 2005-07-20
HUP0000798A2 (en) 2000-10-30
HK1028242A1 (en) 2001-02-09
US6740669B1 (en) 2004-05-25
CZ253398A3 (en) 1999-04-14
PL330764A1 (en) 1999-05-24
DE69813560T2 (en) 2004-02-05
DK0994864T3 (en) 2003-07-21
CY2007014I2 (en) 2009-11-04
PL330798A1 (en) 1999-06-07
IL125732A (en) 2002-12-01
JP3672575B2 (en) 2005-07-20
JP2000516259A (en) 2000-12-05
JP2000516258A (en) 2000-12-05
EP0994864A1 (en) 2000-04-26
CA2256013A1 (en) 1998-12-17
LU91345I2 (en) 2007-09-04
US20010037029A1 (en) 2001-11-01
SK283685B6 (en) 2003-12-02
ID27660A (en) 2001-04-19
AU725517B2 (en) 2000-10-12
EP0994863B1 (en) 2003-02-19
TW403740B (en) 2000-09-01
ATE237599T1 (en) 2003-05-15
US8076362B2 (en) 2011-12-13
ZA984967B (en) 1999-01-11
HU226107B1 (en) 2008-04-28
EP0994863A1 (en) 2000-04-26
RU2194041C2 (en) 2002-12-10
SK283734B6 (en) 2003-12-02
WO1998056773A1 (en) 1998-12-17
CZ292481B6 (en) 2003-09-17
SI0994864T1 (en) 2003-10-31
HUP0002113A2 (en) 2001-02-28
AU725528B2 (en) 2000-10-12
SI0994863T1 (en) 2003-08-31
US20030125568A1 (en) 2003-07-03
LU91345I9 (en) 2018-12-31
CO4940452A1 (en) 2000-07-24
AR012946A1 (en) 2000-11-22
SK109398A3 (en) 1998-12-02
HK1028241A1 (en) 2001-02-09
ID21014A (en) 1999-04-08
CZ253498A3 (en) 1999-04-14
CA2256015C (en) 2008-06-03
ZA984966B (en) 1999-01-11
FR07C0037I1 (en) 2007-08-17
ES2197485T3 (en) 2004-01-01
DK0994863T3 (en) 2003-05-26
CN1132820C (en) 2003-12-31
HUP0002113A3 (en) 2002-09-30
EP0994864B1 (en) 2003-04-16
AR061005A2 (en) 2008-07-30
NO329315B1 (en) 2010-09-27
DE69811500T2 (en) 2004-04-01
CZ292260B6 (en) 2003-08-13
CA2256013C (en) 2007-10-16
KR19990087836A (en) 1999-12-27
SK109498A3 (en) 1998-12-02
UY25844A1 (en) 2001-08-27
CN1259127A (en) 2000-07-05
PT994864E (en) 2003-07-31
TW526195B (en) 2003-04-01
US20100310655A1 (en) 2010-12-09
NL300284I1 (en) 2007-10-01
NO983667D0 (en) 1998-08-11
NO983666L (en) 1998-12-17
US20060116520A1 (en) 2006-06-01
HUP0000798A3 (en) 2000-10-30
CO4940448A1 (en) 2000-07-24
AU8437198A (en) 1998-12-30
CY2007014I1 (en) 2009-11-04
TR199801630T1 (en) 1999-06-21
ATE232852T1 (en) 2003-03-15
PE79799A1 (en) 1999-09-03
PL192114B1 (en) 2006-08-31
IL125733A (en) 2002-12-01
US6455556B2 (en) 2002-09-24
HK1028031A1 (en) 2001-02-02
BR9804947A (en) 1999-08-24
CA2614926A1 (en) 1998-12-17
HU225153B1 (en) 2006-07-28
AR061004A2 (en) 2008-07-30
NL300284I2 (en) 2007-11-01
NZ331371A (en) 2000-08-25
AU8437298A (en) 1998-12-30
RU2198167C2 (en) 2003-02-10
CN1298708C (en) 2007-02-07
PL191943B1 (en) 2006-07-31
FR07C0037I2 (en) 2008-05-16
US7750028B2 (en) 2010-07-06
KR19990087835A (en) 1999-12-27
US20040167186A1 (en) 2004-08-26
AR012945A1 (en) 2000-11-22
DE122007000051I1 (en) 2007-11-08
PE80999A1 (en) 1999-09-06
CN1217716A (en) 1999-05-26
MY120156A (en) 2005-09-30
NO329314B1 (en) 2010-09-27
CN1159300C (en) 2004-07-28
CN1572789A (en) 2005-02-02
KR100425656B1 (en) 2004-05-17
MY125854A (en) 2006-08-30
WO1998056772A1 (en) 1998-12-17
KR100409168B1 (en) 2004-01-31
DE69813560D1 (en) 2003-05-22
IL125732A0 (en) 1999-04-11
IL125733A0 (en) 1999-04-11

Similar Documents

Publication Publication Date Title
CA2256015A1 (en) Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic
LU91145I9 (en)
CA2407100A1 (en) 1-aroyl-piperidinyl benzamidines
CA2255951A1 (en) Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
IL116078A (en) Substituted heterocyclic compounds capable of inhibiting serine proteases and pharmaceutical compositions containing them
CA2276455A1 (en) Phthalazinones
PT741716E (en) ANALOGOS OF DELTA 12,13-ISO-TAXOL ITS ANTI-NEOPLASTIC USE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
MX9605023A (en) Imidazolidine-2,4-dione substituted compounds, as pharmaceutically active substances.
HK1041255A1 (en) N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them
NZ237023A (en) 17beta-substituted-4-aza-5alpha-androstan-3-ones and pharmaceutical compositions
AU2673095A (en) {a}-annelated pyrrole derivatives and pharmaceutical use thereof
EP1126836A4 (en) Benzamide potassium channel inhibitors
HUP0203376A3 (en) 5-aryl-1h-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them and their use
CA2371012A1 (en) 4-(1h-pyrrol-1-yl) imidazoles
BG103399A (en) New heterocycle-substituted benzamides and their application for the treatment of diseases
AU2672895A (en) (a)-annelated pyrrole derivatives and pharmaceutical use thereof
CA2270177A1 (en) Transdermal administration of ment
CA2245267A1 (en) Crystal form of n-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
IL131407A0 (en) Tetrahydropyrido compounds medicaments containing the same and the use thereof
CA2219359A1 (en) Hydantoin derivatives as intermediates for pharmaceutical active compounds
CA2094806A1 (en) Aminosulfonyl urea acat inhibitors
DE69715173D1 (en) Bisarylcyclobutenderivate als cyclooxygenasehemmer
AU3744100A (en) Bicyclo(3.3.1)nonenes useful for the treatment of diabetes
WO2001005228A3 (en) Fungicidal combinations of active substances
CA2225156A1 (en) Use of unsubstituted and substituted n-(pyrrol-1-yl)pyridinamines as anticonvulsant agents

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20180608